EURneffy Nasal Spray: A New Option for Severe Allergy Treatment

From October 2025, a new way to treat severe allergic reactions will become available in the UK. EURneffy, an adrenaline nasal spray, is showing promising real-world results and could offer an alternative to traditional injectable devices like EpiPen and Jext.

Research from the United States involving more than 500 patients shows that around nine in ten people experiencing anaphylaxis were successfully treated with a single dose of Neffy or EURneffy. This success rate is comparable to the outcomes seen with injectable adrenaline, which is currently the standard treatment.

A Needle-Free Option for Those Who Need It

Many people feel anxious about carrying or using injectable adrenaline because of needle fear or uncertainty about administering it correctly. These anxieties can cause delays in treatment, which may lead to worse outcomes during an allergic emergency. EURneffy is small, easy to carry and needle-free, which may help people use adrenaline more quickly and confidently when symptoms begin.

The British Society for Allergy and Clinical Immunology (BSACI) supports the view that EURneffy could be a suitable option for many patients at risk of anaphylaxis. However, any move away from injectable adrenaline should involve shared decision-making between patients and their clinicians.

When Adrenaline Auto-Injectors Are Still Essential

Although EURneffy is a welcome development, it is not yet an appropriate replacement for adrenaline auto-injectors in certain cases. A recent statement by the BSACI stated that they felt that there was not yet enough evidence, due to a lack of studies, to be sure that EurNeffy would be as effective as intramuscular (IM) adrenaline in certain patient groups, including:

• People who have previously needed more than one dose of adrenaline to control anaphylaxis.
• Those who have experienced severe reactions with low blood pressure, which is more often associated with insect venom allergy.

For these groups, adrenaline auto-injectors remain the recommended treatment.

Expert Insights from ACE Founding Professors

Three of the founding professors at the Allergy Centre of Excellence shared their thoughts on the latest findings and what EURneffy may mean for patients.

Professor George Du Toit noted the importance of the real-world data. He highlighted that the outcomes observed in the United States closely match the historic response rates for injected adrenaline and reinforce the idea that EURneffy can be clinically interchangeable with adrenaline auto-injectors. He also pointed out that this complements the regulatory studies showing similar blood levels and responses between EURneffy and traditional devices.

Professor Adam Fox welcomed the choice EURneffy provides. He explained that for some patients, particularly those who may struggle with needles, the nasal spray could be an excellent option. For others who are already confident using their adrenaline auto-injectors, there may be no need to change. He emphasised the importance of real-world data in guiding informed decisions with patients.

Professor Gideon Lack described EURneffy as a positive addition to the treatment of severe allergic reactions. He explained that fear of injections is one of the biggest barriers to using adrenaline quickly and that a nasal spray could encourage earlier treatment and improve both outcomes and quality of life.

Availability at ACE

EURneffy will be available through our in-house pharmacy, and our clinical team is now able to prescribe it where appropriate following consultation and shared decision-making.

Currently, the 2mg EurNeffy is available, suitable for patients weighing 30kg or more, who would otherwise have an adult 300mcg Jext/Epipen. A 1mg Neffy for children under 30kg is planned for release early next year.

What the Launch Means

The arrival of EURneffy in the UK marks a significant step forward in expanding treatment options for people who are at risk of anaphylaxis. While injectable adrenaline will continue to play a vital role, especially for those at higher risk, the availability of a needle-free alternative may increase confidence, reduce hesitation and support faster treatment.

As more real-world evidence becomes available, clinicians and patients will be better equipped to decide who might benefit most from using EURneffy.